Detalhe da pesquisa
1.
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Lancet Oncol
; 25(4): 463-473, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38467131
2.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood
; 140(8): 839-850, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35605176
3.
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 378(12): 1107-1120, 2018 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562156
4.
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Blood
; 133(19): 2031-2042, 2019 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30842083
5.
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.
Hematol Oncol
; 39(3): 326-335, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739461
6.
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
Br J Haematol
; 189(4): 689-693, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31994178
7.
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
Br J Haematol
; 190(5): 736-740, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32236950
8.
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Blood
; 132(23): 2446-2455, 2018 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30287523
9.
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Blood
; 129(19): 2612-2615, 2017 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28373262
10.
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.
Haematologica
; 104(10): 2053-2060, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31097627
11.
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
Hematol Oncol
; 37(1): 3-14, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30187496
12.
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Am J Hematol
; 94(12): 1353-1363, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31512258
13.
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.
Health Qual Life Outcomes
; 17(1): 173, 2019 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31729982
14.
Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Future Oncol
; 15(19): 2227-2239, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31137964
15.
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
Haematologica
; 103(11): 1889-1898, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29976743
16.
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Haematologica
; 103(7): 1209-1217, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29674504
17.
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Hematol Oncol
; 36(4): 624-632, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29512173
18.
Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
Future Oncol
; 14(8): 681-697, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29243946
19.
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol
; 18(3): 297-311, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28139405
20.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
N Engl J Med
; 371(3): 213-23, 2014 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24881631